Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 16.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,668 shares of the company’s stock after purchasing an additional 6,755 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.06% of Syndax Pharmaceuticals worth $999,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its position in shares of Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock valued at $963,000 after acquiring an additional 991 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Syndax Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after purchasing an additional 1,150 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Syndax Pharmaceuticals by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock valued at $187,000 after buying an additional 1,312 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Syndax Pharmaceuticals by 28.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after buying an additional 1,587 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in Syndax Pharmaceuticals in the second quarter worth approximately $33,000.

Analyst Ratings Changes

Several research analysts have weighed in on SNDX shares. Jefferies Financial Group assumed coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They set a “buy” rating and a $37.00 target price for the company. Stifel Nicolaus raised their price objective on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 26th. Citigroup raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. lowered their target price on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright lifted their price objective on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.89.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $19.13 on Monday. The company has a fifty day moving average of $19.33 and a two-hundred day moving average of $20.70. The company has a market capitalization of $1.63 billion, a PE ratio of -5.66 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. The company’s revenue was up 3499999990.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.64) EPS. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).